AI Insight
This study demonstrates that Mitocurcumin, a mitochondria-targeted compound, effectively reduces tumor growth in fruit fly intestinal stem cell tumors driven by overactive Yorkie protein. The researchers identified thioredoxin reductase (TrxR) as a key molecular target and showed that Mitocurcumin treatment disrupts redox balance, increases reactive oxygen species in tumor cells, triggers cell death, and rewires cellular metabolism. The treatment not only reduced tumor size but also alleviated associated physical symptoms and extended the lifespan of affected flies.
Why it matters
This research identifies a specific vulnerability in cancer-like cells that could inform development of mitochondria-targeted therapies for tumors with similar molecular characteristics in humans. The work validates fruit flies as an efficient model system for testing mitochondria-targeted drugs before moving to more complex mammalian studies, potentially accelerating drug discovery timelines.
Understand the Science
⚠️ Preprint – Noch nicht peer-reviewed
Dieser Artikel wurde noch nicht von unabhängigen Experten begutachtet. Die Ergebnisse sind vorläufig und sollten mit Vorsicht interpretiert werden.
Mitochondria-targeted modulation of redox homeostasis has emerged as a promising strategy for controlling pathological cell proliferation. Here, we investigate the effects of Mitocurcumin in a Yorkie-driven intestinal stem cell tumor model in Drosophila. Using an integrative, genetically tractable approach combining in silico molecular modelling with in vivo functional analyses, we identify thioredoxin reductase (TrxR) as a conserved redox-associated target of Mitocurcumin. Docking and molecular dynamics simulations predict a stable interaction of Mitocurcumin with both Drosophila and mammalian TrxR homologs. Functionally, Mitocurcumin treatment reduces mitotic activity, elevates reactive oxygen species (ROS) selectively within escargot-positive intestinal stem cell population, enhances apoptosis in the tumor-bearing guts, and causes significant mitochondrial membrane depolarization. These cellular effects coincide with dose-dependent regression of Yorkie-induced intestinal hyperplasia. Despite mitochondrial functional impairment, mitochondrial morphology remains largely preserved, suggesting primary disruption of redox buffering rather than structural collapse. Metabolomic profiling of these guts further reveals remodelling of energy metabolism consistent with adaptive responses to oxidative stress. Importantly, Mitocurcumin alleviates tumor-associated organismal bloating and significantly extends lifespan indicating a previously uncharacterized systemic, organism-wide response to Mitocurcumin treatment in an in vivo scenario. Collectively, our findings establish TrxR-mediated redox regulation as a critical vulnerability in Yorkie-driven hyperproliferation and highlight the utility of Drosophila as an integrative in vivo platform for evaluating mitochondria-targeted bioactive molecules.